TAH-1005 is under clinical development by Alpha Fusion and currently in Phase I for Follicular Thyroid Cancer. According to GlobalData, Phase I drugs for Follicular Thyroid Cancer have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TAH-1005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TAH-1005 overview

TAH-1005 ([211At] NaAt) is under development for the treatment of papillary thyroid cancer, and follicular thyroid cancer. The drug candidate is [211At] sodium astatide (NaAt) based radiopharmaceutical and is administered through intravenous route.

Alpha Fusion overview

Alpha Fusion focuses on the development and discovery of astatine-based drugs with focus in the field of radiopharmaceuticals for the treatment of cancer diseases. It is headquartered in Osaka City, Osaka, Japan.

For a complete picture of TAH-1005’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.